PDS Biotechnology (PDSB) Q3 2024 earnings summary

Executive summary

• Strong investor and investigator interest in the VERSATILE-003 phase III trial for HPV16-positive head and neck cancer, with trial modifications to reduce cost and time to interim data readout; FDA clearance for the updated IND expected by mid-December 2024 and trial initiation in Q1 2025.

• VERSATILE-002 data show improved median overall survival (30 months) and objective response rates (36%), supporting the new trial design.

• Additional pipeline progress includes promising phase II IMMUNOCERV data in cervical cancer and ongoing development of PDS01ADC for prostate cancer.

• PDS Biotechnology is a clinical-stage immunotherapy company with no commercial products or revenue to date, and continues to advance its Versamune and PDS01ADC clinical programs.

• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months due to recurring losses and the need for additional capital.

Financial highlights

• Net loss for Q3 2024 was $10.7 million ($0.29 per share), slightly improved from $10.8 million ($0.35 per share) in Q3 2023, mainly due to lower operating expenses.

• Operating expenses for Q3 2024 were $10.2 million, down from $10.5 million year-over-year; research and development expenses rose to $6.8 million, while general administrative expenses fell to $3.4 million.

• Cash and cash equivalents totaled $49.8 million as of September 30, 2024.

• Cash used in operating activities was $26.8 million for the nine months ended September 30, 2024.

• $19.4 million was raised from equity sales in the first nine months of 2024.

Outlook and guidance

• VERSATILE-003 trial expected to begin enrolling in Q1 2025, with enrollment projected to complete in 18 months and interim data readout about six months later.

• The company expects continued operating losses and negative cash flows for the foreseeable future and may never become profitable.

• Management plans to fund operations through additional equity or debt financing, collaborations, or government funding, but there is no assurance of success.

• Ongoing evaluation of next steps for IMMUNOCERV in cervical cancer, with advisory board input guiding future development.

• If unable to secure sufficient financing, the company may delay, reduce, or eliminate R&D programs or grant rights to third parties.